Can a common diabetes drug protect hearts on dialysis?

NCT ID NCT05179668

Completed Disease control Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tested whether dapagliflozin, a drug used for diabetes, can improve heart structure in people with kidney failure who are on dialysis. Researchers compared the drug to a placebo in 220 adults. The goal was to see if it could reduce heart muscle thickening, a common problem in dialysis patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dialyseinstitut Dr. Waller

Feldbach, 8330, Austria
Dialyseinstitut Gießauf GmbH

Graz, Austria
Hanusch Krankenhaus

Vienna, 1140, Austria
Klinik Donaustadt

Vienna, 1220, Austria
Klinik Favoriten

Vienna, 1100, Austria
Klinik Landstraße

Vienna, 1030, Austria
Krankenhaus Hietzing

Vienna, 1130, Austria
Medical University of Vienna

Vienna, 1090, Austria
Wiener Dialysezentrum

Vienna, 1220, Austria

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE DIABETES MELLITUS TYPE 2 HEMODIALYSIS KIDNEY FAILURE LEFT VENTRICULAR HYPERTROPHY